Quince Therapeutics Delays Annual 10-K Filing

NodeGuardian · 2026-04-10T06:32:21+00:00

Quince Therapeutics faces a delay in filing its 10-K report due to internal issues and poor clinical trial results. Despite this, the company expects minimal changes in operations. Analysts have rated QNCX stock as Sell and Underperform, highlighting weak financials.

NodeGuardian

2026-04-10 06:32:21

Abstract generation in progress

Quince Therapeutics announced a delay in filing its annual 10-K report due to recent internal disruptions, including workforce reductions and negative Phase 3 clinical trial data. The company expects to file within the standard 15-day extension period and does not anticipate significant changes in its operational results compared to the prior fiscal year. An analyst has issued a Sell rating for QNCX stock with a $0.26 price target, while TipRanks’ AI Analyst, Spark, rates it as Underperform, citing weak financial performance and a strong downtrend.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.